Elutia Inc. (ELUT)

Compare

2.8200

+0.0500

+(1.81%)

As of 2:09:15 PM EDT. Market Open.

Elutia to Participate in Upcoming Investor Conferences

SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences: LD Micro 15th Annual Invitational – New York, NYFormat: Presentation and 1x1 Meetings Presentation Date and Time: Thursday, April 10, 2025, 12:30 p.m. ET (9:30 a.m. PT)We

GlobeNewswire 6 hours ago

ELUT
+1.81%
Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025 SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut of its EluPro™ Antibiotic-Eluting BioEnvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society’s annual meeting (HRS 2025). Attendees will have the opportunity to experience fi

GlobeNewswire 22 hours ago

ELUT
+1.81%
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Seventh GPO Agreement Signed Since EluPro’s Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Advantus Health Partners (“Advantus”), to provide access of Elutia’s EluPro™ Antibiotic Eluting BioEnvelope to Advantus’ core group purchasing organizations (GPO) solutions portfolio. “Teaming up with Advantus is another major step forward

GlobeNewswire 6 days ago

ELUT
+1.81%
Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

— Rigorous testing demonstrates robust antimicrobial performance against bacterial strains relevant to cardiac implanted electronic device (CIED) infections — SILVER SPRING, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of new preclinical data in the current issue of Antibiotics, further demonstrating the antimicrobial performance of its antibiotic-eluting biologic

GlobeNewswire 8 days ago

ELUT
+1.81%
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization – SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the fourth quarter and full year ended December 31, 2024. Business Highlights: Strong Initial Market Uptake for EluPro: Since its pilot launch in the fourth quarter, Elu

GlobeNewswire 27 days ago

ELUT
+1.81%
Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using

GlobeNewswire last month

ELUT
+1.81%
Private equity firms are Elutia Inc.'s (NASDAQ:ELUT) biggest owners and were hit after market cap dropped US$3.9m

Key Insights Elutia's significant private equity firms ownership suggests that the key decisions are influenced by...

Simply Wall St. last month

ELUT
+1.81%
Elutia Announces $15.0 Million Registered Direct Offering

SILVER SPRING, Md., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 5,520,000 shares of the Company’s Class A common stock at a purchase price of $2.50 per share and 480,000 prefunded warrants to purchase up to 480,000 shares of the Company’s Class A common stock at a purchase price of $2.499 per prefunded warrant in a registered direct offering. The pre

GlobeNewswire last month

ELUT
+1.81%
Elutia announces full U.S. commercial launch of EluPro

Elutia (ELUT) announced the U.S. commercial launch of EluPro, an FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices and neurostimulators. This full launch follows a successful pilot program in which EluPro was introduced at select hospitals, demonstrating strong physician adoption and positive patient outcomes. During this initial phase, Elutia has submitted EluPro for approval with 136 hospital value analysis committees, initiated sales at 70 i

TipRanks 2 months ago

ELUT
+1.81%
Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand

First FDA-Cleared Antibiotic-Eluting BioEnvelope Now Available in U.S. for Implantable Pacemakers, Defibrillators, and Neurostimulators SILVER SPRING, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, announced the U.S. commercial launch of EluPro™, the first and only FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators. “EluPro is an exciting innovatio

GlobeNewswire 2 months ago

ELUT
+1.81%
Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners

SILVER SPRING, Md., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Vizient for the benefit of Southern Strategic Sourcing Partners (S3P), to provide access to Elutia’s innovative EluPro™ Antibiotic Eluting BioEnvelope to S3P’s extensive network of 993 acute care facilities, starting immediately. EluPro is the world’s first and only antibiotic-eluting biolo

GlobeNewswire 2 months ago

ELUT
+1.81%
Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.

SILVER SPRING, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced it has been awarded a national group purchasing agreement for Cardiac Rhythm Management Devices with Premier, Inc. Effective November 15, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the EluPro™ Antibiotic-Eluting BioEnvelope. “We ar

GlobeNewswire 3 months ago

ELUT
+1.81%
Elutia Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Elutia ( NASDAQ:ELUT ) Third Quarter 2024 Results Key Financial Results Revenue: US$5.92m (down 3.3% from 3Q 2023). Net...

Simply Wall St. 4 months ago

ELUT
+1.81%
Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers

GlobeNewswire 4 months ago

ELUT
+1.81%
Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024.

GlobeNewswire 4 months ago

ELUT
+1.81%
Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024

SILVER SPRING, Md., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that it will release its third quarter 2024 financial results after market close on Thursday, November 14, 2024. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following in

GlobeNewswire 5 months ago

ELUT
+1.81%
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XVII Conference in Los Angeles on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET). LD Micro Main Event XVII ConferencePresentation Date: Wednesday, October 30, 2024Presentation Time: 2:00 p.m. PT (5:00 p.m. ET)Webcast: Click here Elu

GlobeNewswire 5 months ago

ELUT
+1.81%
SWK Holdings Provides Portfolio Update

Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 /SWK Holdings Corporation (Nasdaq:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized ...

ACCESS Newswire 5 months ago

DERM

ELUT
+1.81%
AOTI.L
Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices

EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model SILVER SPRING, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced the publication of preclinical data demonstrating that EluPro, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA), clears bacterial contamination associa

GlobeNewswire 6 months ago

ELUT
+1.81%
Elutia Celebrates First Year

Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible. On September 6, 2023, as part of a strategic shift toward drug-eluting biologics, the company rebranded as Elutia Inc. and established the mission of “Humanizing Medicine so Patients can Thri

GlobeNewswire 6 months ago

ELUT
+1.81%

Performance Overview

Return	ELUT	S&P 500 (^GSPC)
YTD	-24.60%	-7.71%
1-Year	-10.76%	+4.16%
3-Year	-55.10%	+19.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Elutia Inc. (ELUT)

Elutia to Participate in Upcoming Investor Conferences

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

Private equity firms are Elutia Inc.'s (NASDAQ:ELUT) biggest owners and were hit after market cap dropped US$3.9m

Elutia Announces $15.0 Million Registered Direct Offering

Elutia announces full U.S. commercial launch of EluPro

Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand

Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners

Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.

Elutia Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

SWK Holdings Provides Portfolio Update

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices

Elutia Celebrates First Year

Performance Overview